Risk and Reward in the Orphan Drug Industry
© 2019 Portfolio Management Research. All rights reserved. Thanks to a combination of scientific advances and economic incentives, the development of therapeutics to treat rare or orphan diseases has grown dramatically in recent years. With the advent of Food and Drug Administration–approved gene th...
Main Authors: | Lo, Andrew W, Thakor, Richard T |
---|---|
Format: | Article |
Language: | English |
Published: |
Pageant Media US
2021
|
Online Access: | https://hdl.handle.net/1721.1/134802 |
Similar Items
-
Risk and Reward in the Orphan Drug Industry
by: Lo, Andrew W, et al.
Published: (2022) -
Financing drug discovery for orphan diseases
by: Gromatzky, Austin A., et al.
Published: (2014) -
International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
by: Eun Young Shin, et al.
Published: (2024-12-01) -
Rare diseases and orphan drugs.
by: Aronson, J
Published: (2006) -
Orphan drugs and rare diseases /
by: Pryde, David C., editor, et al.
Published: (2014)